Comparative effectiveness of pharmacological interventions on mortality and the average length of hospital stay of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials

References

• Wang M-Y, Zhao R, Gao L-J, et al. SARS-CoV-2: structure, biology, and structure-based therapeutics development. Front Cell Infect Microbiol. 2020;10:587269–587269.
   PubMed Web of Science ®Google Scholar
• Weekly operational update on COVID-19-9 August 2021 9 8 2021 who.int: world health organization; Available from: https://www.who.int/publications/m/item/weekly-operational-update-on-covid-19—9-august-2021
   Google Scholar
• Tian T, Zhang J, Hu L, et al. Risk factors associated with mortality of COVID-19 in 3125 counties of the United States. Infect Dis Poverty. 2021;10(1):1–8.
   PubMed Web of Science ®Google Scholar
• Zhang X-B, Hu L, Ming Q, et al. Risk factors for mortality of coronavirus disease-2019 (COVID-19) patients in two centers of Hubei province, China: a retrospective analysis. PloS One. 2021;16(1):e0246030.
   PubMed Web of Science ®Google Scholar
• Sepandi M, Taghdir M, Alimohamadi Y, et al. Factors associated with mortality in COVID-19 patients: a systematic review and meta-analysis. Iran J Public Health. 2020;49(7):1211.
   PubMed Web of Science ®Google Scholar
• Consortium WST. Repurposed antiviral drugs for COVID-19—interim WHO SOLIDARITY trial results. N Engl J Med. 2021;384(6):497–511.
   PubMed Web of Science ®Google Scholar
• Angus DC, Derde L, Al-Beidh F, et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial. Jama. 2020;324(13):1317–1329.
   PubMed Web of Science ®Google Scholar
• Horby PW, Estcourt L, Peto L, et al. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv. 2021 2021.03.09.21252736 .
   Google Scholar
• Abeldaño Zuñiga RA, Coca SM, Abeldaño GF, et al. Clinical effectiveness of drugs in hospitalized patients with COVID-19: a systematic review and meta-analysis. Ther Adv Respir Dis. 2021;15:17534666211007214.
   Web of Science ®Google Scholar
• Juul S, Nielsen EE, Feinberg J, et al. Interventions for treatment of COVID-19: of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project). PloS One. 2021;16(3):e0248132.
   PubMed Web of Science ®Google Scholar
• Diallo A, Carlos-Bolumbu M, Traoré M, et al. An updated systematic review and network meta-analysis of 25 randomized trials assessing the efficacy and safety of treatments in COVID-19 disease. J Public Health Res. 2021;10:1.
   Web of Science ®Google Scholar
• Welte T, Ambrose LJ, Sibbring GC, et al. Current evidence for COVID-19 therapies: a systematic literature review. Eur Respir Rev. 2021;30:159.
   Web of Science ®Google Scholar
• Ma -L-L, Wang -Y-Y, Yang Z-H, et al. Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: what are they and which is better? Mil Med Res. 2020;7(1): 7-7.
   Web of Science ®Google Scholar
• Elhusseiny KM, Fa-e A-E, Kamel MG. Possible therapeutic agents for COVID-19: a comprehensive review. Expert Rev Anti Infect Ther. 2020;18(10):1005–1020.
   PubMed Web of Science ®Google Scholar
• Thomas E, Ghany MG, Liang TJ. The application and mechanism of action of ribavirin in therapy of hepatitis C. Antiviral Chem Chemother. 2012;23(1):1–12.
   PubMedGoogle Scholar
• Pei L, Zhang S, Huang L, et al. Antiviral agents, glucocorticoids, antibiotics, and intravenous immunoglobulin usage in 1142 patients with coronavirus disease 2019: a systematic review and meta-analysis. Pol Arch Intern Med. 2020. DOI:https://doi.org/10.20452/pamw.15543.
   Google Scholar
• Houssein M, Fatfat M, Habli Z, et al. Thymoquinone synergizes with arsenic and interferon alpha to target human T-cell leukemia/lymphoma. Life Sci. 2020 Jun;15(251):117639.
   Web of Science ®Google Scholar
• Jockusch S, Tao C, Li X, et al. Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir. Sci Rep. 2020;10(1):1–9.
   PubMed Web of Science ®Google Scholar
• Gupta R, Bhadoria A, Dhamija P. Sofosbuvir for COVID-19. ; 2020;52(3) 232–233.
   Google Scholar
• Jackson WE, Everson GT. Sofosbuvir and velpatasvir for the treatment of hepatitis C. Expert Rev Gastroenterol Hepatol. 2017 Jun;11(6):501–505.
   PubMed Web of Science ®Google Scholar
• Sacramento CQ, Fintelman-Rodrigues N, Temerozo JR, et al. In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19. J Antimicrob Chemother. 2021;76(7):1874–1885 https://doi.org/https://doi.org/10.1093/jac/dkab072 14 12 2021 https://doi.org/https://doi.org/10.1093/jac/dkab072 .
   PubMed Web of Science ®Google Scholar
• Zappulo E, Scotto R, Buonomo AR, et al. Efficacy and safety of a fixed dose combination tablet of asunaprevir + beclabuvir + daclatasvir for the treatment of Hepatitis C. Expert Opin Pharmacother. 2020 Feb;21(3):261–273.
   PubMed Web of Science ®Google Scholar
• Wu X, Yu K, Wang Y, et al. the efficacy and safety of triazavirin for COVID-19: a trial protocol. Engineering. 2020 [2020 october 01];6(10):1199–1204.
   Web of Science ®Google Scholar
• Shahab S, Sheikhi M. Triazavirin-Potential inhibitor for 2019-nCoV Coronavirus M protease: a DFT study. Curr Mol Med. 2020;20. DOI:https://doi.org/10.2174/1566524020666200521075848
   Google Scholar
• Karpenko I, Deev S, Kiselev O, et al. Antiviral properties, metabolism, and pharmacokinetics of a novel azolo-1,2,4-triazine-derived inhibitor of influenza A and B virus replication. Antimicrob Agents Chemother. 2010;54(5):2017–2022.
   PubMed Web of Science ®Google Scholar
• Almasi F, Mohammadipanah F. Hypothetical targets and plausible drugs of coronavirus infection caused by SARS-CoV-2. Transbound Emerg Dis. 2021;68(2):318–332.
   PubMed Web of Science ®Google Scholar
• Ōmura S, Crump A. Ivermectin and malaria control. Malar J. 2017;16(1):1–3.
   PubMed Web of Science ®Google Scholar
• Das RR, Jaiswal N, Dev N, et al. Efficacy and safety of anti-malarial drugs (Chloroquine and Hydroxy-Chloroquine) in treatment of COVID-19 Infection: a systematic review and meta-analysis. Front Med (Lausanne). 2020;7: 482-482.
   Web of Science ®Google Scholar
• Alfaro-Lara R, Espinosa-Ortega HF, Arce-Salinas CA. Systematic review and meta-analysis of the efficacy and safety of leflunomide and methotrexate in the treatment of rheumatoid arthritis. Reumatol Clin (Engl Ed). 2019 May-Jun;15(3):133–139.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Ding C. Effects of Hydrocortisone on Regulating Inflammation, Hemodynamic Stability, and Preventing Shock in Severe Sepsis Patients. Med Sci Monit. 2018;24:3612–3619.
   PubMed Web of Science ®Google Scholar
• Tharmarajah E, Buazon A, Patel V, et al. IL-6 inhibition in the treatment of COVID-19: a meta-analysis and meta-regression. J Infect. 2021;82(5):178–185.
   PubMed Web of Science ®Google Scholar
• Khiali S, Rezagholizadeh A, Entezari-Maleki T. A comprehensive review on sarilumab in COVID-19. Expert Opin Biol Ther. 2021;21(5):615–626.
   PubMed Web of Science ®Google Scholar
• Burmester GR, Lin Y, Patel R, et al. Efficacy and safety of sarilumab monotherapy versus Adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. Ann Rheum Dis. 2017 May;76(5):840–847.
   PubMed Web of Science ®Google Scholar
• Maldonado V, Loza-Mejía MA, Chávez-Alderete J. Repositioning of pentoxifylline as an immunomodulator and regulator of the renin-angiotensin system in the treatment of COVID-19. Med Hypotheses. 2020;144:109988.
   PubMed Web of Science ®Google Scholar
• Semotiuk D, Tolokh O, Rudnitska N. Treatment of sarcoidosis–pentoxifylline. Eur Respir Soc. 2019 54 suppl 63 PA1958 doi:https://doi.org/10.1183/13993003.congress-2019.PA1958 .
   Google Scholar
• Annamaraju P, Baradhi KM. Pentoxifylline. statPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2021, StatPearls Publishing LLC; 2021.
   Google Scholar
• Ahmed MH, Hassan A. Dexamethasone for the treatment of coronavirus disease (COVID-19): a review. SN Compr Clin Med. 2020;2(12) ;1–10 .
   Google Scholar
• Hajialilo M, Ghorbanihaghjo A, Valaee L, et al. A double-blind randomized comparative study of triamcinolone hexacetonide and dexamethasone intra-articular injection for the treatment of knee joint arthritis in rheumatoid arthritis. Clin Rheumatol. 2016 Dec;35(12):2887–2891.
   PubMed Web of Science ®Google Scholar
• COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) treatment guidelines. National Institutes of Health 8 7 2021.https://www.covid19treatmentguidelines.nih.gov/[July8,2021].
   Google Scholar
• Karamanou M, Tsoucalas G, Pantos K, et al. Isolating colchicine in 19th century: an old drug revisited. Curr Pharm Des. 2018;24(6):654–658.
   PubMed Web of Science ®Google Scholar
• Caricchio R, Abbate A, Gordeev I, et al. Effect of canakinumab vs placebo on survival without invasive mechanical ventilation in patients hospitalized with severe COVID-19: a randomized clinical trial. Jama. 2021 Jul 20;326(3):230–239.
   PubMed Web of Science ®Google Scholar
• Zhuang L, Chen J, Yu J, et al. Dosage considerations for canakinumab in children with periodic fever syndromes. Clin Pharmacol Ther. 2019 Sep;106(3):557–567.
   PubMed Web of Science ®Google Scholar
• Taylor PC, Adams AC, Hufford MM, et al. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat Rev Immunol. 2021 [2021 june 01];21(6):382–393.
   PubMed Web of Science ®Google Scholar
• Lopardo G, Belloso WH, Nannini E, et al. RBD-specific polyclonal F (ab´) 2 fragments of equine antibodies in patients with moderate to severe COVID-19 disease: a randomized, multicenter, double-blind, placebo-controlled, adaptive phase 2/3 clinical trial. EClinicalMedicine. 2021;34:100843.
   PubMedGoogle Scholar
• Sultana J, Cutroneo PM, Crisafulli S, et al. Azithromycin in COVID-19 patients: pharmacological mechanism, clinical evidence and prescribing guidelines. Drug Saf. 2020;43(8):691–698.
   PubMed Web of Science ®Google Scholar
• Duarte M, Pelorosso F, Nicolosi LN, et al. Telmisartan for treatment of Covid-19 patients: an open multicenter randomized clinical trial. EClinicalMedicine. 2021 [2021 july 01];37:100962.
   PubMedGoogle Scholar
• Lumley T. Network meta-analysis for indirect treatment comparisons. Stat Med. 2002 Aug 30;21(16):2313–2324.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002 Jun 15;21(11):1539–1558.
   PubMed Web of Science ®Google Scholar
• Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. Jama. 2020;324(11):1048–1057.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569–1578.
   PubMed Web of Science ®Google Scholar
• Madsen LW. Remdesivir for the treatment of Covid-19-final report. N Engl J Med. 2020;338(19):1813–1826.
   Google Scholar
• Davoudi-Monfared E, Rahmani H, Khalili H, et al. A randomized clinical trial of the efficacy and safety of interferon β-1a in treatment of severe COVID-19. Antimicrob Agents Chemother. 2020;64:9.
   Web of Science ®Google Scholar
• Ader F, Peiffer-Smadja N, Poissy J, et al. An open-label randomized, controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19. Clin Microbiol Infect. 2021. DOI:https://doi.org/10.1016/j.cmi.2021.05.020.
   Google Scholar
• Rahmani H, Davoudi-Monfared E, Nourian A, et al. Interferon β-1b in treatment of severe COVID-19: a randomized clinical trial. Int Immunopharmacol. 2020 [2020 Nov 01];88:106903.
   PubMed Web of Science ®Google Scholar
• Zheng F, Zhou Y, Zhou Z, et al. SARS-CoV-2 clearance in COVID-19 patients with Novaferon treatment: a randomized, open-label, parallel-group trial. Int J Infect Dis. 2020 Oct;99:84–91.
   PubMed Web of Science ®Google Scholar
• Sadeghi A, Ali Asgari A, Norouzi A, et al. Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial. J Antimicrob Chemother. 2020 Nov 1;75(11):3379–3385.
   PubMed Web of Science ®Google Scholar
• Roozbeh F, Saeedi M, Alizadeh-Navaei R, et al. Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial. J Antimicrob Chemother. 2021;76(3):753–757.
   PubMed Web of Science ®Google Scholar
• Sayad B, Khodarahmi R, Najafi F, et al. Efficacy and safety of sofosbuvir/velpatasvir versus the standard of care in adults hospitalized with COVID-19: a single-centre, randomized controlled trial. J Antimicrob Chemother. 2021;76:2158–2167.
   PubMed Web of Science ®Google Scholar
• Wu X, Yu K, Wang Y, et al. Efficacy and safety of triazavirin therapy for coronavirus disease 2019: a pilot randomized controlled trial. Engineering. 2020 [2020 Oct 01];6(10):1185–1191.
   Web of Science ®Google Scholar
• Li Y, Xie Z, Lin W, et al. Efficacy and safety of lopinavir/ritonavir or arbidol in adult patients with mild/moderate COVID-19: an exploratory randomized controlled trial. Med. 2020;1(1):105–113. e4
   PubMed Web of Science ®Google Scholar
• Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020 May 7;382(19):1787–1799.
   PubMed Web of Science ®Google Scholar
• Reis G, EAdSM S, Silva DCM, et al. Effect of early treatment with hydroxychloroquine or lopinavir and ritonavir on risk of hospitalization among patients with covid-19: the together randomized clinical trial. JAMA Network Open. 2021;4(4):e216468–e216468.
   PubMed Web of Science ®Google Scholar
• Arabi YM, Gordon AC, Derde LP, et al. Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial. Intensive Care Med. 2021 47 8 ;1–20.
   PubMed Web of Science ®Google Scholar
• Ivashchenko AA, Dmitriev KA, Vostokova NV, et al. AVIFAVIR for treatment of patients with moderate COVID-19: interim results of a phase II/III multicenter randomized clinical trial. medRxiv. 2020 2020.07.26.20154724 .
   Google Scholar
• Udwadia ZF, Singh P, Barkate H, et al. Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: a randomized, comparative, open-label, multicenter, phase 3 clinical trial. Inter J Infect Dis. 2021;103:62–71.
   PubMed Web of Science ®Google Scholar
• Chen J, Xia L, Liu L, et al. editors. Antiviral activity and safety of darunavir/cobicistat for the treatment of COVID-19. Open Forum Infect Dis. 2020 7 7 ofaa241 . Oxford University Press US
   PubMed Web of Science ®Google Scholar
• López-Medina E, López P, Hurtado IC, et al. Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: a randomized clinical trial. Jama. 2021;325(14):1426–1435 .
   PubMed Web of Science ®Google Scholar
• Ahmed S, Karim MM, Ross AG, et al. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. Inter J Infect Dis. 2021;103:214–216.
   PubMed Web of Science ®Google Scholar
• Okumuş N, Demirtürk N, Çetinkaya RA, et al. Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients. BMC Infect Dis. 2021;21(1):1–11.
   PubMed Web of Science ®Google Scholar
• Abd‐Elsalam S, Noor RA, Badawi R, et al. Clinical Study Evaluating the Efficacy of Ivermectin in COVID‐19. ; 2021 93 10 5833–5838 .
   Google Scholar
• Shahbaznejad L, Davoudi A, Eslami G, et al. Effects of ivermectin in patients with COVID-19: a multicenter, double-blind, randomized, controlled clinical trial. Clin Ther. 2021;43(6):1007–1019 .
   PubMed Web of Science ®Google Scholar
• Mahmud R, Rahman MM, Alam I, et al. Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial. J Int Med Res. 2021;49(5):03000605211013550.
   Web of Science ®Google Scholar
• Vallejos J, Zoni R, Bangher M, et al. Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial. BMC Infect Dis. 2021;21(1):1–11.
   PubMed Web of Science ®Google Scholar
• Niaee MS, Namdar P, Allami A, et al. Ivermectin as anadjunct treatment for hospitalized adult COVID-19 patients: a randomized multi-center clinical trial. Asian Pac J Trop Med. 2021;14(6):266–273.
   Web of Science ®Google Scholar
• Á R-N, Bernardelli RS, Bmd C, et al. An open-label randomized controlled trial evaluating the efficacy of chloroquine/hydroxychloroquine in severe COVID-19 patients. Sci Rep. 2021;11(1):1–10.
   PubMed Web of Science ®Google Scholar
• Mitjà O, Corbacho-Monné M, Ubals M, et al. Hydroxychloroquine for early treatment of adults with mild Covid-19: a randomized-controlled trial. Clinl Infect Dis. 2020;73(11): e4073–e4081 .
   Web of Science ®Google Scholar
• Lyngbakken MN, Berdal J-E, Eskesen A, et al. A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics. Nat Commun. 2020;11(1):1–6.
   PubMed Web of Science ®Google Scholar
• Kamran SM, Moeed HA, Naseem A, et al. Clearing the fog: is hydroxychloroquine effective in reducing coronavirus disease-2019 progression? a randomized controlled trial. Cureus. 2021;13:3.
   Web of Science ®Google Scholar
• Cavalcanti AB, Zampieri FG, Rosa RG, et al. Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. N Engl J Med. 2020;383(21):2041–2052.
   PubMed Web of Science ®Google Scholar
• Dubée V, Roy P-M, Vielle B, et al. Hydroxychloroquine in mild-to-moderate COVID-19: a placebo-controlled double blind trial. Clin Microbiol Infect. 2021;27(8):1124–1130 .
   PubMed Web of Science ®Google Scholar
• Skipper CP, Pastick KA, Engen NW, et al. Hydroxychloroquine in nonhospitalized adults with early COVID-19: a randomized trial. Ann Intern Med. 2020;173(8):623–631.
   PubMed Web of Science ®Google Scholar
• Abd-Elsalam S, Esmail ES, Khalaf M, et al. Hydroxychloroquine in the treatment of COVID-19: a multicenter randomized controlled study. Am J Trop Med Hyg. 2020;103(4):1635–1639.
   PubMed Web of Science ®Google Scholar
• Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. Bmj. 2020 May;14(369):m1849.
   Web of Science ®Google Scholar
• Schwartz I, Boesen ME, Cerchiaro G, et al. Assessing the efficacy and safety of hydroxychloroquine as outpatient treatment of COVID-19: a randomized controlled trial. CMAJ Open. 2021;9(2):E693–E702.
   PubMedGoogle Scholar
• Pouladzadeh M, Safdarian M, Eshghi P, et al. A randomized clinical trial evaluating the immunomodulatory effect of convalescent plasma on COVID-19-related cytokine storm. Intern Emerg Med. 2021;10:1–11.
   Google Scholar
• Group RC. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet 2021; 397:10289 2049–2059 . (London, England).
   PubMed Web of Science ®Google Scholar
• Gharbharan A, Jordans CC, GeurtsvanKessel C, et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. Nat Commun. 2021;12(1):1–12.
   PubMed Web of Science ®Google Scholar
• Sekine L, Arns B, Fabro BR, et al. Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial. Eur Respir J 2021 2101471 https://doi.org/10.1183/13993003.01471-2021
   Google Scholar
• Gottlieb RL, Nirula A, Chen P, et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. Jama. 2021;325(7):632–644.
   PubMed Web of Science ®Google Scholar
• Lundgren JD, Grund B, Barkauskas CE, et al. A neutralizing monoclonal antibody for hospitalized patients with Covid-19. N Engl J Med. 2020;384(10):905–914 .
   PubMed Web of Science ®Google Scholar
• Tabarsi P, Barati S, Jamaati H, et al. Evaluating the effects of Intravenous Immunoglobulin (IVIg) on the management of severe COVID-19 cases: a randomized controlled trial. Int Immunopharmacol. 2021 Jan;90:107205.
   PubMed Web of Science ®Google Scholar
• Gharebaghi N, Nejadrahim R, Mousavi SJ, et al. The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial. BMC Infect Dis. 2020;20(1):1–8.
   Web of Science ®Google Scholar
• Furtado RH, Berwanger O, Fonseca HA, et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet. 2020;396(10256):959–967.
   PubMed Web of Science ®Google Scholar
• Abaleke E, Abbas M, Abbasi S, et al. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397(10274):605–612.
   PubMed Web of Science ®Google Scholar
• Sekhavati E, Jafari F, SeyedAlinaghi S, et al. Safety and effectiveness of azithromycin in patients with COVID-19: an open-label randomised trial. Int J Antimicrob Agents. 2020;56(4):106143.
   PubMed Web of Science ®Google Scholar
• Hinks TS, Cureton L, Knight R, et al. Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial. Lancet Respir Med. 2021;9:1130–1140.
   PubMed Web of Science ®Google Scholar
• Butler CC, Dorward J, Yu L-M, et al. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet. 2021;397(10279):1063–1074.
   PubMed Web of Science ®Google Scholar
• Oldenburg CE, Pinsky BA, Brogdon J, et al. Effect of oral azithromycin vs placebo on COVID-19 symptoms in outpatients with SARS-CoV-2 infection: a randomized clinical trial. Jama. 2021;326:490.
   PubMed Web of Science ®Google Scholar
• JamaliMoghadamSiahkali S, Zarezade B, Koolaji S, et al. Safety and effectiveness of high-dose vitamin C in patients with COVID-19: a randomized open-label clinical trial. Eur J Med Res. 2021;26(1):1–9.
   PubMed Web of Science ®Google Scholar
• Geriak M, Haddad F, Kullar R, et al. Randomized prospective open label study shows no impact on clinical outcome of adding losartan to hospitalized COVID-19 patients with mild hypoxemia. Infect Dis Ther. 2021;10(3) ;1–8.
   Web of Science ®Google Scholar
• Abulmeaty M, Aljuraiban GS, Shaikh SM, et al. the efficacy of antioxidant oral supplements on the progression of COVID-19 in non-critically ill patients: a randomized controlled trial. Antioxidants. 2021;10(5):804.
   Web of Science ®Google Scholar
• Zarehoseinzade E, Allami A, Ahmadi M, et al. Finasteride in hospitalized adult males with COVID-19: a risk factor for severity of the disease or an adjunct treatment: a randomized controlled clinical trial. Medical Journal of the Islamic Republic of Iran (MJIRI). 2021;35(1):232–237.
   Google Scholar
• Fan S, Zhen Q, Chen C, et al. Clinical efficacy of low-dose emetine for patients with COVID-19: a real-world study. Journal of Bio-X Research. 2021;4(2):53.
   PubMedGoogle Scholar
• Siami Z, Aghajanian S, Mansouri S, et al. Effect of Ammonium Chloride in addition to standard of care in outpatients and hospitalized COVID-19 patients: a randomized clinical trial. Inter J Infect Dis. 2021;108:306–308.
   PubMed Web of Science ®Google Scholar
• Duarte M, Pelorosso F, Nicolosi LN, et al. Telmisartan for treatment of Covid-19 patients: an open multicenter randomized clinical trial. EClinicalMedicine. 2021;37:100962.
   PubMedGoogle Scholar
• Wang M, Zhao Y, Hu W, et al. Treatment of COVID-19 patients with prolonged post-symptomatic viral shedding with leflunomide–a single-center, randomized, controlled clinical trial. Clin Infect Dis. 2020;73(11): e4012–e4019 .
   Web of Science ®Google Scholar
• Dequin P-F, Heming N, Meziani F, et al. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomized clinical trial. Jama. 2020;324(13):1298–1306.
   PubMed Web of Science ®Google Scholar
• Maldonado V, Hernandez-Ramírez C, Oliva-Pérez EA, et al. Pentoxifylline decreases serum LDH levels and increases lymphocyte count in COVID-19 patients: results from an external pilot study. Int Immunopharmacol. 2021 Jan;90:107209.
   PubMed Web of Science ®Google Scholar
• Corral-Gudino L, Bahamonde A, Arnaiz-Revillas F, et al. Methylprednisolone in adults hospitalized with COVID-19 pneumonia. Wien Klin Wochenschr. 2021;133(7):303–311.
   PubMed Web of Science ®Google Scholar
• Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. Jama. 2020;324(13):1307–1316.
   PubMed Web of Science ®Google Scholar
• Wootton D. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med. 2021;384(8):693–704.
   PubMed Web of Science ®Google Scholar
• Lopes MI, Bonjorno LP, Giannini MC, et al. Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial. RMD Open. 2021;7(1):e001455.
   PubMed Web of Science ®Google Scholar
• Tardif J-C, Bouabdallaoui N, L’Allier PL, et al. Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial. Lancet Respir Med. 2021;9:924–932.
   PubMed Web of Science ®Google Scholar
• Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2021;384(9):795–807.
   PubMed Web of Science ®Google Scholar
• Caricchio R, Abbate A, Gordeev I, et al. Effect of canakinumab vs placebo on survival without invasive mechanical ventilation in patients Hospitalized with severe COVID-19: a randomized clinical trial. Jama. 2021;326(3):230–239.
   PubMed Web of Science ®Google Scholar
• Veiga VC, Prats JA, Farias DL, et al. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. Bmj. 2021 372 ;n84.
   PubMed Web of Science ®Google Scholar
• Salama C, Han J, Yau L, et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021;384(1):20–30.
   PubMed Web of Science ®Google Scholar
• Zhao H, Zhu Q, Zhang C, et al. Tocilizumab combined with favipiravir in the treatment of COVID-19: a multicenter trial in a small sample size. Biomed Pharmacother. 2021;133:110825.
   PubMed Web of Science ®Google Scholar
• Stone JH, Frigault MJ, Serling-Boyd NJ, et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med. 2020;383(24):2333–2344.
   PubMed Web of Science ®Google Scholar
• Wang D, Fu B, Peng Z, et al. Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial. Front Med. 2021;9:1–9.
   Google Scholar
• Investigators R-C. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med. 2021;384(16):1491–1502.
   PubMed Web of Science ®Google Scholar
• Rosas IO, Bräu N, Waters M, et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. N Engl J Med. 2021;384(16):1503–1516.
   PubMed Web of Science ®Google Scholar
• Soin AS, Kumar K, Choudhary NS, et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respir Med. 2021;9(5):511–521.
   PubMed Web of Science ®Google Scholar
• Lescure F-X, Honda H, Fowler RA, et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021;9:522–532.
   PubMed Web of Science ®Google Scholar
• Sterne JA, Murthy S, Diaz JV, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. Jama. 2020;324(13):1330–1341.
   PubMed Web of Science ®Google Scholar
• Perveen RA, Nasir M, Talha KA, et al. Systematic review on current antiviral therapy in COVID-19 pandemic. Med J Malaysia. 2020 Nov;75(6):710–716.
   PubMedGoogle Scholar
• Pulakurthi YS, Pederson JM, Saravu K, et al. Corticosteroid therapy for COVID-19: a systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2021;100(20):e25719–e25719.
   PubMed Web of Science ®Google Scholar
• Pan H, Peto R, Henao-Restrepo AM, et al. Repurposed antiviral drugs for Covid-19 - Interim WHO solidarity trial results. N Engl J Med. 2021 Feb 11;384(6):497–511.
   PubMed Web of Science ®Google Scholar
• Berardicurti O, Ruscitti P, Ursini F, et al. Mortality in tocilizumab-treated patients with COVID-19: a systematic review and meta-analysis. Clin Exp Rheumatol. 2020;38(6):1247–1254.
   PubMed Web of Science ®Google Scholar
• Aziz M, Haghbin H, Abu Sitta E, et al. Efficacy of tocilizumab in COVID‐19: a systematic review and meta‐analysis. J Med Virol. 2020;93:1620–1630: 3 .
   PubMed Web of Science ®Google Scholar
• Kim MS, An MH, Kim WJ, et al. Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: a systematic review and network meta-analysis. PLoS Med. 2020;17(12):e1003501.
   PubMed Web of Science ®Google Scholar
• Group RC. Effect of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020;383(21):2030–2040.
   PubMed Web of Science ®Google Scholar
• Self WH, Semler MW, Leither LM, et al. Effect of hydroxychloroquine on clinical status at 14 days in hospitalized patients with COVID-19: a randomized clinical trial. JAMA. 2020;324(21):2165–2176.
   PubMed Web of Science ®Google Scholar
• Mitjà O, Corbacho-Monné M, Ubals M, et al. A cluster-randomized trial of hydroxychloroquine for prevention of Covid-19. N Engl J Med. 2020;384(5):417–427 .
   PubMed Web of Science ®Google Scholar
• Fiolet T, Guihur A, Rebeaud ME, et al. Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis. Clin Microbiol Infect. 2021;27(1):19–27.
   PubMed Web of Science ®Google Scholar
• Sarma P, Kaur H, Kumar H, et al. Virological and clinical cure in COVID‐19 patients treated with hydroxychloroquine: a systematic review and meta‐analysis. J Med Virol. 2020;92(7):776–785.
   PubMed Web of Science ®Google Scholar
• Ayele Mega T, Feyissa TM, Dessalegn Bosho D, et al. The outcome of hydroxychloroquine in patients treated for COVID-19: systematic review and meta-analysis. Can Respir J. 2020 2020 ;4312519–4312519.
   PubMed Web of Science ®Google Scholar
• Padhy BM, Mohanty RR, Das S, et al. Therapeutic potential of ivermectin as add on treatment in COVID 19: a systematic review and meta-analysis. J Pharm Pharm Sci. 2020;23:462–469.
   PubMed Web of Science ®Google Scholar
• Roman YM, Burela PA, Pasupuleti V, et al. Ivermectin for the treatment of COVID-19: a systematic review and meta-analysis of randomized controlled trials. Clin Infect Dis. 2021 Jun;2021.05.21.21257595 doi:https://doi.org/10.1101/2021.05.21.21257595.
   Google Scholar
• Jahanshahlu L, Rezaei N. Monoclonal antibody as a potential anti-COVID-19. Biomed Pharmacother. 2020;129:110337.
   PubMed Web of Science ®Google Scholar